Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
11/14/2017 11/15/2017 11/16/2017 11/17/2017 11/20/2017 Date
1311(c) 1307.5(c) 1318(c) 1308(c) 1314 Last
6 570 446 9 327 107 16 989 213 6 441 460 5 577 778 Volume
-0.61% -0.27% +0.80% -0.76% +0.46% Change
More quotes
Financials ( GBP)
Sales 2017 30 089 M
EBIT 2017 8 449 M
Net income 2017 3 716 M
Debt 2017 14 279 M
Yield 2017 6,12%
Sales 2018 30 541 M
EBIT 2018 8 334 M
Net income 2018 4 260 M
Debt 2018 14 028 M
Yield 2018 6,12%
P/E ratio 2017 18,32
P/E ratio 2018 14,80
EV / Sales2017 2,61x
EV / Sales2018 2,57x
Capitalization 64 336 M
More Financials
Company
‘GlaxoSmithKline Plc is a global healthcare company which engages in developing, manufacturing, and marketing of pharmaceutical products including vaccines, over the counter medicines and health-related consumer products.It operates through the following segments: Pharmaceuticals, Pharmaceuticals... 
Sector
Pharmaceuticals
Calendar
11/29Investor Meeting
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
11/17 GLAXOSMITHKLINE : 10.4% Potential Upside Indicated by Jefferies International
11/17 GLAXOSMITHKLINE : Wolf Administration Official Continues 'Jobs That Pay' Tour at..
11/16 GLAXOSMITHKLINE : Investigators from GlaxoSmithKline plc Release New Data on Pne..
11/16 GLAXOSMITHKLINE : New Cytokines Findings from GlaxoSmithKline Outlined [Identifi..
11/16 GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc Provides New Data on Chronic..
11/16 GLAXOSMITHKLINE : Reports from GlaxoSmithKline plc Provide New Insights into Vac..
11/16 GLAXOSMITHKLINE : Data from GlaxoSmithKline Advance Knowledge in Bipolar Disorde..
11/16 Europe approves GlaxoSmithKline's new triple lung drug
11/16 GLAXOSMITHKLINE : Trelegy Ellipta EU approval for treatment of COPD
11/16 GLAXOSMITHKLINE : Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains..
More news
Sector news : Pharmaceuticals - NEC
02:50pDJSHIRE : Appoints Thomas Dittrich as Chief Financial Officer
02:16pDJSHIRE PLC SHIRE PLC : Directorate Change
12:24pDJROCHE : Shares Rise on Positive Results From Clinical Trials
08:19aDJNOVARTIS : Secures EU Approval for Tasigna Treatment in Children
11/18DJADRs End Higher; JA Solar, NetEase Trade Actively
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on GLAXOSMITHKLINE 
GLAXOSMITHKLINE  - 2015
This could be the time to buy
BUY
GLAXOSMITHKLINE - 2014
Bearish signal below GBp 1415
SELL
More Strategies
News from SeekingAlpha
02:23a Tracking Tweedy Browne Portfolio - Q3 2017 Update
11/17 YOUR DAILY PHARMA SCOOP : Gilead CAR-T Potential, Egalet Surges, Aerie Launches ..
11/16 Glaxo's inhaled triplet therapy for COPD OK'd in Europe
11/15 WALL STREET BREAKFAST : Order War At The Dubai Airshow
11/14 Glaxo And Pfizer Are Top 'Safer' Dividend Healthcare Gainers For November
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 15,7  GBP
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-16.26%85 003
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550